MARKET

SVA

SVA

Sinovac Biotech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.47
0.00
0.00%
Suspension 16:00 04/24 EDT
OPEN
--
PREV CLOSE
6.47
HIGH
--
LOW
--
VOLUME
0
TURNOVER
--
52 WEEK HIGH
6.58
52 WEEK LOW
6.25
MARKET CAP
639.90M
P/E (TTM)
88.15
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
EMERGING MARKETS-Brazil's real rises, with eyes on vaccination campaign
reuters.com · 1h ago
Duterte says Filipinos can use Pfizer vaccine, but touts Sinovac deal
reuters.com · 2h ago
Sao Paulo's Butantan says vaccination output depends on ingredients from China
reuters.com · 4h ago
EMERGING MARKETS-Most Latam currencies subdued; eyes on Brazil's vaccination campaign
reuters.com · 6h ago
Sinovac says its COVID-19 vaccine more effective with longer dosing interval
reuters.com · 8h ago
UPDATE 1-Brazil to begin vaccination campaign on Monday afternoon
reuters.com · 8h ago
UPDATE 2-Brazil vaccinations start nationwide as country faces vaccine ingredient shortfall
reuters.com · 8h ago
Brazil to begin vaccination campaign on Monday afternoon
reuters.com · 9h ago
More
Forecast
EPSBVPSCFPS
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SVA. Analyze the recent business situations of Sinovac Biotech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Institutional Holdings
Institutions: 34
Institutional Holdings: 23.09M
% Owned: 23.34%
Shares Outstanding: 98.90M
TypeInstitutionsShares
Increased
0
0
New
5
198
Decreased
3
3.49K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.43%
Pharmaceuticals & Medical Research
+0.21%
Key Executives
Chairman/Chief Executive Officer/President/Secretary/Director
Weidong Yin
Chairman/Chief Executive Officer/President/Secretary/Director
WeiDong Yin
Chief Financial Officer/Vice President
Nan Wang
Vice President/Director of Sales/Director of Marketing
Xiaomei Yin
Director
Jianzeng Cao
Vice President
Qiang Gao
Director
Fung Qiu Hoi
Vice President
Jing Li
Independent Director
Simon Anderson
Director
Pengfei Li
Director
Guowei Wang
Independent Director
Shan Fu
Independent Director
Jue Lee
Independent Director
Kenneth Lee
Independent Director
Yuk Lam Lo
Independent Director
Meng Mei
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SVA
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Sinovac Biotech Ltd. stock information, including NASDAQ:SVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SVA stock methods without spending real money on the virtual paper trading platform.